Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 QLT Doses First IDA Patient | Contract Pharma

What are you searching for?

Sign in
Trials & Filings

QLT Doses First IDA Patient

Trial covers 60 and older subjects with Impaired Dark Adaptation

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

QLT Inc. has dosed the first patient has been dosed in the Phase IIa proof-of-concept trial of QLT091001 in adult subjects with Impaired Dark Adaptation (IDA), a condition that results in decreased ability to recover visual sensitivity in the dark after exposure to bright lights.
 
The randomized, multi-center, parallel-group, placebo-controlled trial covers subjects (age 60 or older) with IDA, or impaired low luminance low contrast best corrected visual acuity (LLLC BCVA) in at least one eye and having no known ophthalmic pathologies to explain their condition other than early age-related macular degeneration (AMD). Patients will be enrolled at sites in the U.S. Subjects will be randomized to receive placebo or one of two different doses (10 or 40 mg/m2) of QLT091001 once per week for three consecutive weeks with one additional dose the day after the third dose. The trial is designed to evaluate the safety profile and effects of QLT091001 on impaired dark adaptation time, glare recovery time and LLLC BCVA.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics